TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma
- PMID: 39798580
- DOI: 10.1016/S0140-6736(24)02680-1
TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma
Conflict of interest statement
FPR has received honoraria for lectures, consulting activities, and travel support from the Falk Foundation, AbbVie, Gilead, Ipsen, AstraZeneca, Roche, and Novartis. AG is advisory board or steering committee member to AbbVie, Advanz, Albireo, Alexion, AstraZeneca, Bayer, Bristol Myers Squibb, CSL Behring, Eisai, Falk, Gilead, Heel, Intercept, Ipsen, Merz, MSD, Novartis, NovoNordisk, Pfizer, Roche, Sanofi-Aventis, and Sequana, and a speaker for Orphalan.
Comment on
-
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.Lancet. 2025 Jan 18;405(10474):203-215. doi: 10.1016/S0140-6736(24)02575-3. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798578 Clinical Trial.
-
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous